Browsing Category
Trending
Astellas Pharma obtains Universal Cells
Astellas Pharma has acquired Universal Cells. Astellas will gain Universal Cells’ proprietary Universal Donor Cell technology to create cell therapy products that do not require Human…
Read More...
Read More...
Spineology finishes enrollment in IDE Trial for Mesh Fusion Transplant
Spineology is exhilarated to declare that enrollment stands complete in the SCOUT clinical trial. The SCOUT (Spineology Clinical Outcomes Trial) IDE, conducted under an FDA-approved…
Read More...
Read More...
FDA concedes Glooko’s Mobile Insulin Dosing System
Glooko declared that the US FDA has conceded its Mobile Insulin Dosing System (MIDS) for the titration of long-acting insulin for people with type 2 diabetes.
The system includes…
Read More...
Read More...
OTTR partners Hemasoft to facilitate transfusion medicine
OTTR, the leading provider of organ transplant patient tracking software that improves the quality of patient care via workflow management, has partnered with Hemasoft, an international…
Read More...
Read More...
IRX Therapeutics commences Phase 2 Clinical Trial for CIN3 or VIN3 women
IRX Therapeutics asserted that Phase 2 double-blind, randomized, placebo-controlled clinical trial of IRX-2 in women has commenced with squamous cervical intraepithelial neoplasia 3…
Read More...
Read More...
Neurocrine Biosciences files NDA for opicapone for Parkinson’s disease
Neurocrine Biosciences announced that the US FDA has provided assistance on the regulatory path forward to support the New Drug Application for opicapone, an investigational drug for…
Read More...
Read More...
FDA sanctions breakthrough treatment for specific kind of Prostate Cancer
FDA has approved a certain Erleada for the treatment of patient inflicted with prostate cancer that has not spread (non-metastatic), but that continues to grow despite treatment with…
Read More...
Read More...
J&J Pharmaceuticals announce approval of ERLEADA by FDA for NM-CRPC patients
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the approval of ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the treatment of…
Read More...
Read More...
FDA accepts Ortho Dermatologics JEMDEL for Plaque Psoriasis Treatment
Division of Valeant Pharmaceuticals International, Inc., Ortho Dermatologics asserted that the U.S Food and Drug Administration accepted the New Drug Application for JEMDEL …
Read More...
Read More...
Dr. Christine Esau appointed VP of Research and Development for Arcturus Therapeutics
Ace RNA medicines company, Arcturus Therapeutics asserted the appointment of Dr. Christine Esau, Senior Director of Translational Research, as Vice President of Research and…
Read More...
Read More...
Lynn Lewis appointed Senior VP Global Sales of Envigo
Leading provider of nonclinical contract research services and research models, Envigo asserted the appointment of Lynn Lewis to the position of Senior Vice President, Global Sales.…
Read More...
Read More...
FDA paves way for marketing of Viz.AI Contact application
U.S Food and Drug Administration paved way for the marketing of the Viz.AI Contact application which is a type of clinical decision support software designed to interpret computed…
Read More...
Read More...
Michael Nolte appointed CEO of Bracket
Leading clinical trial technology and specialty services provider, Bracket declared the appointment of Michael Nolte as the company's Chief Executive Officer. Michael Nolte served as…
Read More...
Read More...
Trovagene declares activation of 2 supplementary Clinical Trial sites to conduct Phase 1b/2 Study
Precision medicine biotechnology company, developing targeted oncology therapeutics, Trovagene asserted the addition of two leading institutions,Yale Cancer Center and principal…
Read More...
Read More...
Martha A.Q. Curley, PhD appointed the Ruth M. Colket Endowed Chair at CHOP
Martha A.Q .Curley, PhD, RN, FAAN, a professor in Nursing Science at the University of Pennsylvania's School of Nursing, has been appointed the Ruth M. Colket Endowed Chair in Pediatric…
Read More...
Read More...
Phase II CONDOR Trial suggests tolerance of inhibitor durvalumab in patients with metastatic head…
Astro's Interpretation of the Phase II CONDOR trial suggests that the immune checkpoint inhibitor durvalumab is tolerable among heavily pre-treated patients with recurrent or metastatic…
Read More...
Read More...
Astro declares positive results of phase II OPTIMA Clinical trial
Astro indicates positive results of phase II OPTIMA Clinical Trial signifying that patients with head and neck cancers associated with the human papillomavirus (HPV), including those…
Read More...
Read More...
Quidel seeks 510 (k) Clearance for QuickVue Influenza A+B Test complying FDA’s Class II RIDT…
Quidel Corporation who is known for providing diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, sought 510 (k) Clearance from the United…
Read More...
Read More...
MOLOGEN forays into global co-development agreement with ONCOLOGIE for lead compound lefitolimod
Biopharmaceutical company MOLOGEN AG declared having signed a license deal for the Chinese territory and a global co-development agreement between MOLOGEN and ONCOLOGIE Inc. for its…
Read More...
Read More...
ProBioGen and TEVA sign license agreement on HuALN Technology
ProBioGen announced the signature of a non-exclusive license agreement on its proprietary human Artificial Lymph Node (HuALN) platform technology with TEVA. The unique human Artificial…
Read More...
Read More...